Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
canagliflozin (464) 464
humans (450) 450
index medicus (427) 427
diabetes mellitus, type 2 - drug therapy (381) 381
hypoglycemic agents - therapeutic use (318) 318
diabetes (253) 253
type 2 diabetes (252) 252
glucose (231) 231
male (226) 226
sodium-glucose transporter 2 - antagonists & inhibitors (217) 217
female (207) 207
endocrinology & metabolism (205) 205
glucosides - therapeutic use (195) 195
dapagliflozin (192) 192
middle aged (186) 186
double-blind (179) 179
canagliflozin - therapeutic use (178) 178
safety (170) 170
hypoglycemic agents - adverse effects (156) 156
aged (144) 144
empagliflozin (142) 142
efficacy (135) 135
pharmacology & pharmacy (130) 130
sglt2 inhibitor (126) 126
dextrose (124) 124
diabetes mellitus, type 2 - blood (123) 123
metformin (123) 123
treatment outcome (123) 123
type 2 diabetes mellitus (123) 123
diabetes mellitus (121) 121
adult (112) 112
insulin (112) 112
benzhydryl compounds - therapeutic use (111) 111
thiophenes - therapeutic use (109) 109
glycemic control (107) 107
sodium (94) 94
blood glucose - metabolism (92) 92
blood glucose - drug effects (91) 91
glucosides - adverse effects (91) 91
hypoglycemic agents - administration & dosage (90) 90
mellitus (88) 88
medicine, general & internal (86) 86
body weight (85) 85
hypoglycemic agents - pharmacology (83) 83
care and treatment (82) 82
double-blind method (82) 82
blood pressure (80) 80
canagliflozin - adverse effects (80) 80
clinical trials (76) 76
internal medicine (76) 76
inadequate glycemic control (75) 75
analysis (73) 73
drug therapy (71) 71
sglt2 inhibitors (71) 71
sodium-glucose transporter 2 - metabolism (69) 69
diabetes mellitus, type 2 - metabolism (68) 68
drug therapy, combination (66) 66
glycated hemoglobin a - metabolism (66) 66
monotherapy (66) 66
sitagliptin (66) 66
diabetes therapy (64) 64
add-on (63) 63
animals (62) 62
hyperglycemia (61) 61
type-2 diabetes-mellitus (61) 61
risk factors (59) 59
hypoglycemic agents (58) 58
blood pressure - drug effects (57) 57
diabetes mellitus, type 2 - complications (57) 57
medicine & public health (56) 56
randomized controlled trials as topic (55) 55
hypoglycemia (54) 54
thiophenes - adverse effects (53) 53
glucosides - pharmacology (51) 51
cotransporter 2 inhibitor (50) 50
dose-response relationship, drug (50) 50
glucosides - administration & dosage (50) 50
hemoglobin (50) 50
patients (50) 50
canagliflozin - administration & dosage (49) 49
glycosylated hemoglobin (49) 49
canagliflozin - pharmacology (47) 47
hypoglycemia - chemically induced (47) 47
metformin - therapeutic use (47) 47
diabetes mellitus, type 2 - physiopathology (46) 46
glucose cotransporter 2 (46) 46
glucose transporter (46) 46
inhibitors (45) 45
benzhydryl compounds - adverse effects (44) 44
body weight - drug effects (44) 44
glucose metabolism (44) 44
endocrinology (40) 40
medical research (40) 40
risk (40) 40
abridged index medicus (39) 39
insulin resistance (39) 39
original (39) 39
research (39) 39
add-on therapy (38) 38
cardiovascular disease (38) 38
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial
by Schernthaner, Guntram and Gross, Jorge L and Rosenstock, Julio and Guarisco, Michael and Fu, Min and Yee, Jacqueline and Kawaguchi, Masato and Canovatchel, William and Meininger, Gary
Diabetes Care, ISSN 0149-5992, 09/2013, Volume 36, Issue 9, pp. 2508 - 2515
OBJECTIVE-To evaluate the efficacy and safety of canagliflozin, a sodium glucose cotransporter 2 inhibitor, compared with sitagliptin in subjects with type 2... 
INSULIN | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | EFFICACY | DAPAGLIFLOZIN | SAFETY | EXENATIDE EXENDIN-4 | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | COTRANSPORTER 2 INHIBITOR | MELLITUS | BETA-CELL FUNCTION | Hypoglycemic Agents - therapeutic use | Thiophenes - therapeutic use | Metformin - therapeutic use | Double-Blind Method | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Sulfonylurea Compounds - therapeutic use | Male | Treatment Outcome | Pyrazines - therapeutic use | Blood Glucose - drug effects | Canagliflozin | Female | Glucosides - therapeutic use | Aged | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Triazoles - therapeutic use | Type 2 diabetes | Glucose metabolism | Care and treatment | Blood cholesterol | Hypoglycemic agents | Glucose | Pharmaceutical industry | Comparative analysis | Dextrose | Diabetes therapy | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
by Vallon, Volker
Annual Review of Medicine, ISSN 0066-4219, 1/2015, Volume 66, Issue 1, pp. 255 - 270
The kidneys in normoglycemic humans filter 160-180 g of glucose per day (∼30% of daily calorie intake), which is reabsorbed and returned to the systemic... 
body weight | sodium-glucose cotransporter | glucose reabsorption | glomerular hyperfiltration | hypertension | gluconeogenesis | diabetic nephropathy | MEDICINE, RESEARCH & EXPERIMENTAL | SUGAR-TRANSPORT | BLOOD-PRESSURE | HYPERGLYCEMIA | GLUCAGON-LIKE PEPTIDE-1 | GLUCOSE COTRANSPORTER SGLT1 | IMPROVED GLYCEMIC CONTROL | KIDNEY | PROXIMAL TUBULE | CARDIOVASCULAR RISK | Hypoglycemic Agents - therapeutic use | Thiophenes - therapeutic use | Sodium-Glucose Transporter 2 - metabolism | Humans | Diabetes Mellitus, Type 1 - metabolism | Diabetes Mellitus, Type 2 - metabolism | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Diabetes Mellitus, Type 1 - drug therapy | Kidney - metabolism | Canagliflozin | Glucosides - therapeutic use | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Glucose metabolism | Health aspects | Methods | Diabetes therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
by Scheen, André J
Drugs, ISSN 0012-6667, 12/2014, Volume 75, Issue 1, pp. 33 - 59
Inhibitors of sodium-glucose co-transporter type 2 (SGLT2) are proposed as a novel approach for the management of type 2 diabetes mellitus (T2DM). Several... 
ADD-ON THERAPY | RANDOMIZED-CONTROLLED-TRIAL | 1ST GLOBAL APPROVAL | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TOXICOLOGY | PLACEBO-CONTROLLED TRIAL | METFORMIN PLUS SULFONYLUREA | CHRONIC KIDNEY-DISEASE | JAPANESE PATIENTS | INADEQUATE GLYCEMIC CONTROL | BASE-LINE CHARACTERISTICS | Hypoglycemic Agents - therapeutic use | Thiophenes - therapeutic use | Glucosides - pharmacology | Thiophenes - adverse effects | Humans | Thiophenes - pharmacology | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Benzhydryl Compounds - adverse effects | Canagliflozin | Glucosides - therapeutic use | Benzhydryl Compounds - pharmacology | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Hypoglycemic Agents - adverse effects | Glucosides - adverse effects
Journal Article
Details down arrow
4. Full Text Developing Treatments for Chronic Kidney Disease in the 21st Century
by Breyer, Matthew D., MD and Susztak, Katalin, MD, PhD
Seminars in Nephrology, ISSN 0270-9295, 2016, Volume 36, Issue 6, pp. 436 - 447
Summary Chronic kidney disease (CKD) is a lethal and rapidly increasing burden on society. Despite this, there are relatively few therapies in development for... 
Nephrology | Diabetic nephropathy | renal outcomes | SGTL2 | inflammation | Angiotensin | VASCULAR ADHESION PROTEIN-1 | COMPLEMENT INHIBITOR ECULIZUMAB | MONOCYTE CHEMOATTRACTANT PROTEIN-1 | TYPE-2 DIABETIC-NEPHROPATHY | APPROPRIATE THERAPEUTIC TARGET | SHARED TRANSCRIPTIONAL NETWORKS | ANTAGONIST LOSARTAN RENAAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | UROLOGY & NEPHROLOGY | PLACEBO-CONTROLLED TRIAL | POST-HOC ANALYSIS | Hypoglycemic Agents - therapeutic use | Oxidative Stress | Glycosaminoglycans - therapeutic use | Humans | Oleanolic Acid - analogs & derivatives | Diabetic Nephropathies - drug therapy | Sodium-Glucose Transporter 2 Inhibitors | Pyridoxamine - analogs & derivatives | Atrasentan | Drug Discovery | Mineralocorticoid Receptor Antagonists - therapeutic use | Pyrrolidines - therapeutic use | Renal Insufficiency, Chronic - drug therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Canagliflozin - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Glucosides - therapeutic use | Oleanolic Acid - therapeutic use | Endothelin Receptor Antagonists - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Benzhydryl Compounds - therapeutic use | Pyridoxamine - therapeutic use | Please provide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Lower risk of death with SGLT2 inhibitors in observational studies: Real or bias?
by Suissa, Samy
Diabetes Care, ISSN 0149-5992, 01/2018, Volume 41, Issue 1, pp. 6 - 10
Two recent observational studies reported a remarkably lower rate of all-cause death associated with sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in... 
EMPA-REG | IMMORTAL TIME BIAS | HYPOTHESIS | ENDOCRINOLOGY & METABOLISM | Hypoglycemic Agents - therapeutic use | Follow-Up Studies | Bias | Diabetes Mellitus, Type 2 - genetics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Mortality | Risk Factors | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - epidemiology | Randomized Controlled Trials as Topic | Canagliflozin - therapeutic use | Cardiovascular Diseases - epidemiology | Observational Studies as Topic | Glucosides - therapeutic use | Benzhydryl Compounds - therapeutic use | Insulin - therapeutic use | Cohort Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
by Heerspink, Hiddo J. L and Desai, Mehul and Jardine, Meg and Balis, Dainius and Meininger, Gary and Perkovic, Vlado
Journal of the American Society of Nephrology, ISSN 1046-6673, 01/2017, Volume 28, Issue 1, pp. 368 - 375
Sodium-glucose cotransporter 2 inhibition with canagliflozin decreases HbA1c, body weight, BP, and albuminuria, implying that canagliflozin confers... 
TRIAL | ATRIAL-NATRIURETIC-PEPTIDE | GLUCOSE CONTROL | GFR DECLINE | EFFICACY | SAFETY | DOUBLE-BLIND | END-POINTS | CHRONIC KIDNEY-DISEASE | EMPAGLIFLOZIN | KIDNEY-DISEASE | UROLOGY & NEPHROLOGY | TYPE-2 | Hypoglycemic Agents - therapeutic use | Albuminuria - etiology | Double-Blind Method | Canagliflozin - pharmacology | Diabetic Nephropathies - etiology | Humans | Middle Aged | Sulfonylurea Compounds - therapeutic use | Male | Albuminuria - prevention & control | Disease Progression | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Canagliflozin - therapeutic use | Sulfonylurea Compounds - pharmacology | Female | Diabetes Mellitus, Type 2 - drug therapy | Diabetic Nephropathies - prevention & control | Diabetes Mellitus, Type 2 - complications | renal function | Clinical Research | SGLT2 | diabetic nephropathy | canagliflozin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis
by Zaccardi, F and Webb, D. R and Htike, Z. Z and Youssef, D and Khunti, K and Davies, M. J
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2016, Volume 18, Issue 8, pp. 783 - 794
Aim To assess the comparative efficacy and safety of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors in adults with type 2 diabetes. Methods We... 
empagliflozin | dapagliflozin | review | canagliflozin | meta‐analysis | systematic | SGLT2 inhibitor | meta-analysis | RANDOMIZED-CONTROLLED-TRIAL | GLYCEMIC CONTROL | METFORMIN PLUS SULFONYLUREA | CONTROLLED 102-WEEK TRIAL | ADD-ON THERAPY | PARALLEL-GROUP | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PHASE-3 TRIAL | PLACEBO-CONTROLLED TRIAL | JAPANESE PATIENTS | Hypoglycemic Agents - therapeutic use | Body Weight | Fasting | Cholesterol, HDL - metabolism | Glycated Hemoglobin A - metabolism | Humans | Treatment Outcome | Diabetes Mellitus, Type 2 - metabolism | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Reproductive Tract Infections - chemically induced | B-Cell Activating Factor | Urinary Tract Infections - chemically induced | Canagliflozin - therapeutic use | Weight Loss | Glucosides - therapeutic use | Network Meta-Analysis | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemia - chemically induced | Odds Ratio | Benzhydryl Compounds - therapeutic use | Type 2 diabetes | Blood cholesterol | Analysis | Low density lipoproteins | Glycosylated hemoglobin | Urinary tract infections | Glucose | Trans fatty acids | Dextrose | Confidence intervals | Infections | Blood pressure | Diabetes | Cholesterol
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data
by Del Prato, S and Nauck, M and Durán‐Garcia, S and Maffei, L and Rohwedder, K and Theuerkauf, A and Parikh, S
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2015, Volume 17, Issue 6, pp. 581 - 590
Aims To assess the long‐term efficacy and tolerability of dapagliflozin versus glipizide as add‐on to metformin in patients with inadequately controlled type 2... 
type 2 diabetes | SGLT2 inhibitor | dapagliflozin | safety | efficacy | durability | Type 2 diabetes | Durability | Efficacy | Safety | Dapagliflozin | URINARY-TRACT-INFECTIONS | MELLITUS | RANDOMIZED CLINICAL-TRIALS | BODY-WEIGHT | HYPERGLYCEMIA | CANAGLIFLOZIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | COTRANSPORTER 2 INHIBITOR | PLACEBO-CONTROLLED TRIAL | EMPAGLIFLOZIN | Hypoglycemic Agents - therapeutic use | Metformin - therapeutic use | Double-Blind Method | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Male | Treatment Outcome | Glipizide - therapeutic use | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Drug Therapy, Combination - methods | Glomerular Filtration Rate - drug effects | Urinary Tract Infections - chemically induced | Female | Glucosides - therapeutic use | Aged | Blood Pressure - drug effects | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Care and treatment | Analysis | Urinary tract infections | Hypoglycemic agents | Glucose | Dextrose | Diabetes therapy | Confidence intervals | Medical research | Diabetes | Diabetes mellitus | Body weight | Blood pressure | Urinary tract | Metformin | Hypoglycemia | Diabetes mellitus (non-insulin dependent)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
by Shyangdan, Deepson S and Uthman, Olalekan A and Waugh, Norman
BMJ Open, ISSN 2044-6055, 02/2016, Volume 6, Issue 2, p. e009417
ObjectiveBecause of the lack of head-to-head trials, the aim was to indirectly compare sodium glucose transporter-2 (SGLT-2) inhibitors in the treatment of... 
Hypoglycemic Agents - therapeutic use | Metformin - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Sodium-Glucose Transporter 2 Inhibitors | Weight Loss - drug effects | Diabetes Mellitus, Type 2 - blood | Sorbitol - analogs & derivatives | Canagliflozin - therapeutic use | Bayes Theorem | Glucosides - therapeutic use | Blood Pressure - drug effects | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Benzhydryl Compounds - therapeutic use | Sorbitol - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes
by Henry, Robert R and Thakkar, Payal and Tong, Cindy and Polidori, David and Alba, Maria
Diabetes Care, ISSN 0149-5992, 12/2015, Volume 38, Issue 12, pp. 2258 - 2265
OBJECTIVEThis study assessed the efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in adults with type 1... 
GLYCEMIC CONTROL | MANAGEMENT | THERAPY | EVENTS | DAPAGLIFLOZIN | SGLT2 INHIBITOR | ENDOCRINOLOGY & METABOLISM | KETOACIDOSIS | MELLITUS | Canagliflozin - administration & dosage | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Diabetes Mellitus, Type 1 - drug therapy | Hypoglycemic Agents - administration & dosage | Canagliflozin - therapeutic use | Adult | Female | Drug Therapy, Combination | Insulin - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats
by Sa-nguanmoo, Piangkwan and Tanajak, Pongpan and Kerdphoo, Sasiwan and Jaiwongkam, Thidarat and Pratchayasakul, Wasana and Chattipakorn, Nipon and Chattipakorn, Siriporn C
Toxicology and Applied Pharmacology, ISSN 0041-008X, 10/2017, Volume 333, pp. 43 - 50
Dipeptidyl peptidase-4 inhibitor (vildagliptin) has been shown to exert beneficial effects on insulin sensitivity and neuroprotection in obese-insulin... 
Obese-insulin resistance | Vildagliptin | Cognitive function | Mitochondrial function | Dapagliflozin | Synaptic plasticity | METFORMIN | HOMEOSTASIS | COGNITION | DENSITY | PLASMA | CANAGLIFLOZIN | GLUCOSE | PHARMACOLOGY & PHARMACY | TOXICOLOGY | RECEPTOR FUNCTION | Memory - drug effects | Neuroprotective Agents - therapeutic use | Reactive Oxygen Species - metabolism | Insulin - physiology | Nitriles - pharmacology | Obesity - drug therapy | Rats, Wistar | Apoptosis - drug effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Cognition Disorders - metabolism | Male | Membrane Potential, Mitochondrial - drug effects | Brain - physiology | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Brain - metabolism | Neuroprotective Agents - pharmacology | Long-Term Potentiation - drug effects | Diet, High-Fat | Malondialdehyde - blood | Adamantane - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Glucosides - therapeutic use | Benzhydryl Compounds - therapeutic use | Adamantane - analogs & derivatives | Malondialdehyde - metabolism | Adamantane - pharmacology | Cognition Disorders - physiopathology | Glucosides - pharmacology | Anti-Inflammatory Agents - pharmacology | Insulin Resistance | Obesity - physiopathology | Mitochondria - metabolism | Mitochondria - drug effects | Cognition Disorders - drug therapy | Maze Learning - drug effects | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Obesity - metabolism | Brain - drug effects | Animals | Benzhydryl Compounds - pharmacology | Oxidative Stress - drug effects | Mitochondria - physiology | Nitriles - therapeutic use | Obesity | Brain | Insulin resistance | Apoptosis | Analysis and chemistry | Low density lipoproteins | Cognition disorders | Glucose tolerance tests | Blood | High performance liquid chromatography | Neurophysiology | Index Medicus | INSULIN | APOPTOSIS | DRUGS | MITOCHONDRIA | RATS | SENSITIVITY | METABOLIC DISEASES | 60 APPLIED LIFE SCIENCES | BRAIN
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes
by Scheen, André J
Clinical Pharmacokinetics, ISSN 0312-5963, 07/2017, Volume 56, Issue 7, pp. 703 - 718
Type 2 diabetes (T2D) generally requires a combination of several pharmacological approaches to control hyperglycaemia. Combining a sodium-glucose... 
GLUCOSE COTRANSPORTER 2 | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | 1ST GLOBAL APPROVAL | DOUBLE-BLIND TRIAL | HEALTHY-SUBJECTS | TOXICOLOGICAL CONSIDERATIONS | PHARMACOLOGY & PHARMACY | OPEN-LABEL | DAPAGLIFLOZIN ADD-ON | JAPANESE PATIENTS | DRUG-DRUG INTERACTIONS | Canagliflozin - pharmacokinetics | Dipeptides - therapeutic use | Dipeptides - pharmacokinetics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Linagliptin - pharmacokinetics | Treatment Outcome | Glucosides - pharmacokinetics | Linagliptin - therapeutic use | Diabetes Mellitus, Type 2 - metabolism | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Canagliflozin - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate - therapeutic use | Glucosides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Benzhydryl Compounds - therapeutic use | Adamantane - pharmacokinetics | Benzhydryl Compounds - pharmacokinetics |